Ian Ingram | Authors

FDA Approves Abiraterone/Prednisone for Metastatic Prostate Cancer

February 08, 2018

The US Food and Drug Administration has approved abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic prostate cancer patients with high-risk, castration-sensitive disease.

FDA Expands Approval of EGFR Inhibitor for Lung Cancer Treatment

January 17, 2018

The FDA has expanded the approval of afatinib (Gilotrif) to include the first-line treatment of metastatic non–small-cell lung cancer patients whose tumors have non-resistant EGFR mutations, including three newly identified substitution mutations.

FDA Approves Brentuximab Vedotin for Cutaneous Lymphoma

November 10, 2017

The FDA has approved brentuximab vedotin (Adcetris) for the treatment of primary cutaneous anaplastic large-cell lymphoma and CD30-expressing mycosis fungoides in patients who have received prior systemic therapy.

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease

November 09, 2017

The FDA has expanded the approval of vemurafenib (Zelboraf) to include the treatment of Erdheim–Chester disease in adult BRAF V600–positive patients. This marks the first approval from the agency for treating this rare blood cancer.